Safety of selective cyclooxygenase-2 inhibitors in inflammatory bowel disease

American Journal of Gastroenterology

Volumn 97, Issue 4, 2002, Pages 910-914

  Mahadevan, Uma ^a   Loftus Jr, Edward V ^b   Tremaine, William J ^b   Sandborn, William J ^b  

^a UNIVERSITY OF CALIFORNIA   (United States)

^b MAYO CLINIC   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CELECOXIB; CYCLOOXYGENASE 2 INHIBITOR; NONSTEROID ANTIINFLAMMATORY AGENT; ROFECOXIB;

ADULT; AGED; ARTICLE; CLINICAL ARTICLE; COLON ULCER; CROHN DISEASE; DISEASE ACTIVITY; DISEASE EXACERBATION; DRUG INDICATION; DRUG SAFETY; DRUG USE; ENTERITIS; FEMALE; GASTROINTESTINAL SYMPTOM; HUMAN; ILEITIS; KIDNEY FAILURE; MALE; PRIORITY JOURNAL; RASH; ULCERATIVE COLITIS;

ADULT; AGED; COLITIS, ULCERATIVE; CROHN DISEASE; CYCLOOXYGENASE 2; CYCLOOXYGENASE 2 INHIBITORS; CYCLOOXYGENASE INHIBITORS; DISEASE PROGRESSION; FEMALE; HUMANS; INTESTINES; ISOENZYMES; LACTONES; MALE; MEMBRANE PROTEINS; MIDDLE AGED; POUCHITIS; PROSTAGLANDIN-ENDOPEROXIDE SYNTHASES; PYRAZOLES; RETROSPECTIVE STUDIES; SEVERITY OF ILLNESS INDEX; SULFONAMIDES; SULFONES;

EID: 0036123619     PISSN: 00029270     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0002-9270(02)03964-3     Document Type: Article

References (30)

1. Inducible isoforms of cyclooxygenase and nitric-oxide synthase in inflammation
2. Gastrointestinal tract complications of nonsteroidal anti-inflammatory drug treatment in rheumatoid arthritis. A prospective observational cohort study
3. A randomized trial comparing the effect of rofecoxib, a cyclooxygenase 2-specific inhibitor, with that of ibuprofen on the gastroduodenal mucosa of patients with osteoarthritis. Rofecoxib Osteoarthritis Endoscopy Study Group
4. Anti-inflammatory and upper gastrointestinal effects of celecoxib in rheumatoid arthritis: A randomized controlled trial
5. Non-steroidal anti-inflammatory drugs are associated with emergency admission to hospital for colitis due to inflammatory bowel disease
6. Effects of nonsteroidal antiinflammatory drugs on inflammatory bowel disease: A case-control study
7. Nonsteroidal anti-inflammatory drugs activate quiescent inflammatory bowel disease
8. Relapse of ulcerative proctocolitis during treatment with non-steroidal anti-inflammatory drugs
9. Tolerance of nonsteroidal antiinflammatory drugs in patients with inflammatory bowel disease
10. Association between analgesic use and inflammtory bowel disease flares: A retrospective cohort study
11. Management of Crohn's disease in adults
12. Disease activity courses in a regional cohort of Crohn's disease patients
13. Clinical, endoscopic, and histologic spectrum of nonsteroidal anti-inflammatory drug-induced lesions in the colon
14. The histopathology of nonsteroidal anti-inflammatory drug-associated colitis
15. Acute colitis associated with etodolac
16. Use of nonsteroidal anti-inflammatory drugs in outpatients with inflammatory bowel disease
17. Cyclooxygenase 2 is induced in colonic epithelial cells in inflammatory bowel disease
18. Expression of cyclooxygenase-2 mRNA in active inflammatory bowel disease
19. Induction of cyclooxygenase 2 in gastric mucosal lesions and its inhibition by the specific antagonist delays healing in mice
20. Role of cyclooxygenase-2 in the healing of gastric ulcers in rats
21. Exacerbation of inflammation-associated colonic injury in rat through inhibition of cyclooxygenase-2
22. Cyclo-oxygenase-2 inhibitors ameliorate the severity of experimental colitis in rats
23. Selective COX-2 inhibitors and human inflammatory bowel disease
24. Exacerbation of inflammatory bowel disease associated with use of celecoxib
25. Treatment of peripheral arthropathy in IBD with rofecoxib, a selective COX-2 inhibitor
26. Aspirin use and reduced risk of fatal colon cancer
27. Treatment of colonic and rectal adenomas with sulindac in familial adenomatous polyposis
28. The cyclooxygenase-2 inhibitor celecoxib is a potent preventive and therapeutic agent in the min mouse model of adenomatous polyposis
29. The effect of celecoxib, a cyclooxygenase-2 inhibitor, in familial adenomatous polyposis
30. The role of cyclooxygenase 2 in ulcerative colitis-associated neoplasia